Olink^® Target and Explore HT — from Rules-Based Medicine

Protein biomarkers are critical in understanding the mechanism of action behind different diseases and evaluating a patient’s therapeutic response. Rules-Based Medicine—a leader in proteomic testing for the past 20 years—performs Olink testing to improve the efficiency and precision of your clinical trials. Olink’s proximity extension assay (PEA^®) delivers the throughput you need without compromising specificity or scalability. Whether you need a small panel of focused biomarkers or a comprehensive exploratory assessment, RBM has an Olink option to meet your needs. 

Exceptional Science

• The Olink PEA technology employs a dual-recognition approach using antibody pairs labeled with complementary DNA oligonucleotides. When the antibody pair binds to the target protein, the oligonucleotides are brought into proximity and hybridize, creating a unique DNA barcode. This DNA barcode is then extended and amplified by polymerase chain reaction (PCR), and measured by quantitative PCR (qPCR) or next-generation sequencing (NGS). PEA provides enhanced sensitivity and specificity, as mismatched oligonucleotides do not hybridize to form a barcode, and, thus, no signal is generated.

Service Excellence

• RBM is an Olink Target Service Provider, delivering the results you expect on a timeline to meet your requirements. Complete this contact form to get a quote on your next Olink project.

Choose Olink assays from RBM for:

• Exceptional sensitivity and specificity

  • Detect proteins at femtograms per milliliter

• Low sample volume

  • Numerous assays performed from a single sample

• Built-in quality controls

  • Internal and external controls in all biomarker panels

• Scalability

  • Take your findings from discovery toward clinical translation

• Disease-specific panels

  • Measure the markers most relevant to your therapeutic area of interest

Olink is well suited to:

• Evaluate therapeutic effects

  • Accurately measure at baseline and after treatment to understand the dynamic changes associated with a therapeutic candidate.

• Understand disease onset and mechanism of action

  • Certain biomarkers are present years before diagnosis. Olink can help identify the relevant proteomic changes.

• Develop biomarker signatures

  • Explore HT measures thousands of proteins at once. Longitudinal studies can help you understand proteomic profiles for different diseases.

• Drug target identification

  • Disease-specific proteomic signatures can help identify potential drug targets.

Click each panel below to download an Excel file of the included analytes.